Mandate

Vinge has assisted Novozymes Biopharma DK A/S

November 08, 2011

Vinge has assisted Novozymes Biopharma DK A/S in the sale of Novozymes Biopharma Sweden AB to Repligen Corporation. Novozymes is the world leader in bio innovation with industrial enzymes, microorganisms, and biopharmaceutical ingredients as its business. Novozymes generated sales of DKK 9,724 million and EBIT of DKK 2,117 million in 2010.

Repligen Corporation is a leading supplier of critical technologies and ingredients used to manufacture biologic drugs. Repligen's corporate headquarters are in Massachusetts, USA.

Vinge’s team has primarily consisted of Björn Mullaart (partner), Karin Ebbinghaus (senior associate and Karin Engström (associate).

Related

Vinge advises Pricer in connection with Vusion’s public takeover offer

On 17 November 2026, VusionGroup S.A., a French public limited company listed on Euronext Paris, announced a recommended public takeover offer to the shareholders of Pricer Aktiebolag (publ) to acquire all shares in Pricer for a consideration of SEK 6.00 per share. The offer values all shares in Pricer at approximately SEK 980.4 million.
November 20, 2026

Vinge has advised Rite Ventures in connection with sale of shares in Qliro AB (publ)

Vinge has advised Rite Ventures in connection with the sale of shares in Qliro AB (publ) to Svea Bank AB (publ).
November 19, 2026

Vinge advises Röko AB (publ) in connection with the establishment of its MTN programme

Vinge has advised Röko AB (publ) ("Röko") on the establishment of a medium-term note programme (the "MTN Programme") with a framework amount of SEK 5 billion.
November 13, 2026